Funders › CT › The Multiple Myeloma Research Foundation Inc › 2023
Grants paid by The Multiple Myeloma Research Foundation Inc, tax year 2023
EIN 06-1504413 · Norwalk, CT · Form 990, Schedule I · NTEE G50
In tax year 2023, The Multiple Myeloma Research Foundation Inc (EIN 06-1504413) reported 21 grants paid totaling $6,594,759. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2023
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2023 | Icahn School of Medicine at Mount Sinai New York, NY | A | $1,964,644 | paid | SITE INVESTMENT GRANT, IMMUNOTHERAPY | 202422689349300902 |
| 2023 | Dana Farber Cancer Institute Boston, MA | A | $1,050,000 | paid | SITE INVESTMENT GRANT, IMMUNOTHERAPY, PREVENTION | 202422689349300902 |
| 2023 | Washington University in St Louis St Louis, MO | A | $806,802 | paid | SITE INVESTMENT GRANT, IMMUNOTHERAPY | 202422689349300902 |
| 2023 | Emory University Atlanta, GA | A | $613,060 | paid | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY, PREVENTION | 202422689349300902 |
| 2023 | Beth Israel Deaconess Medical Center Boston, MA | A | $612,829 | paid | SITE INVESTMENT GRANT, IMMUNOTHERAPY | 202422689349300902 |
| 2023 | Mayo Clinic - Rochester Rochester, MN | A | $405,695 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Ucsf Myeloma Research Program San Francisco, CA | A | $150,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | City of Hope Durate, CA | U | $130,000 | paid | SITE INVESTMENT GRANT, FELLOW, IMMUNOTHERAPY | 202422689349300902 |
| 2023 | University of Texas- Southwestern Medical Center Dallas, TX | A | $110,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Hackensack University Medical Center Hackensack, NJ | A | $101,729 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Memorial Sloan-Kettering Cancer Center New York, NY | A | $100,000 | paid | SITE INVESTMENT GRANT, FELLOW, TRANSLATIONAL CORE, PREVENTION | 202422689349300902 |
| 2023 | The University of Chicago Chicago, IL | A | $100,000 | paid | SITE INVESTMENT GRANT, FELLOW | 202422689349300902 |
| 2023 | Barbara Ann Karmanos Cancer Hospital Detroit, MI | A | $100,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Sarah Cannon Research Institute LLC Nashville, TN | A | $100,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | The Regents of the University of California San Francisco San Francisco, CA | A | $60,000 | paid | IMMUNOTHERAPY | 202422689349300902 |
| 2023 | Ohio State University Research Foundation Columbus, OH | A | $55,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Levine Cancer Center Charlotte, NC | A | $50,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Massachusetts General Hospital Boston, MA | A | $42,500 | paid | SITE INVESTMENT GRANT, IMMUNOTHERAPY | 202422689349300902 |
| 2023 | University of Michigan Ann Arbor, MI | A | $25,000 | paid | SITE INVESTMENT GRANT | 202422689349300902 |
| 2023 | Be the Match Foundation Minneapolis, MN | A | $10,000 | paid | IMMUNOTHERAPY | 202422689349300902 |
| 2023 | Indiana University Bloomington, IN | A | $7,500 | paid | FELLOW | 202422689349300902 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990 e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.